Baseline Power of Theta Oscillations Predicts Mystical-Type Experiences Induced by DMT in a Natural Setting
Enzo Tagliazucchi, Federico Zamberlán, Federico Cavanna, Laura De la Fuente, Celeste Romero, Yonatan Sanz Perl, Carla Pallavicini
Frontiers in Psychiatry November 5, 2021 DOI: 10.3389/fpsyt.2021.720066 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Sample size | 35 |
| Population | Healthy volunteers |
| Intervention | Inhaled DMT |
| Topics | DMT Mystical experience |
| Keywords | Electroencephalography Consciousness Feeling Audiology Developmental psychology |
| Citations | 23 |
| Key findings | Baseline fronto-temporal theta oscillations inversely predict the intensity of mystical-type experiences induced by inhaled DMT. |
Abstract
N,N-Dimethyltryptamine (DMT) is a classic psychedelic capable of inducing short-lasting but profound changes in consciousness. As with other psychedelics, the experience induced by DMT strongly depends upon contextual factors, yet the neurobiological determinants of this variability remain unknown. The present study investigated changes in neural oscillations elicited by inhaled DMT, and whether baseline electroencephalography (EEG) recordings could predict the subjective effects reported by the participants. Healthy volunteers ( N = 35) were measured with EEG before and during the acute effects of DMT consumed in a natural setting. Source-localized neural oscillations were correlated with the results of multiple questionnaires employed to assess the subjective effects of the drug. DMT resulted in a marked reduction of alpha and beta oscillations, and increased posterior spectral power in the delta, theta and gamma bands. The power of fronto-temporal theta oscillations was inversely correlated with scales indexing feelings of unity and transcendence, which are an integral part of the phenomenology of mystical-type experiences. The robustness of these results was supported using a machine learning model for regression trained and tested following a cross-validation procedure. These results are consistent with the observation that the state of mind prior to consuming a psychedelic drug influences the ensuing subjective experience of the user. They also suggest that baseline EEG screenings before administration of a serotonergic psychedelic could be useful to estimate the likelihood of inducing mystical-type experiences, previously linked to sustained positive effects in well-being and improved outcome of therapeutic interventions.
Comparable studies
Other observational and cohort studies on DMT, most cited first.
Citations in the library
Cited by 19
- A neurophenomenological approach to non-ordinary states of consciousness: hypnosis, meditation, and psychedelics Trends in Cognitive Sciences December 22, 2022
- Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study Translational Psychiatry August 2, 2022
- N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine Human Psychopharmacology: Clinical and Experimental February 17, 2022
- An Encounter With the Other: A Thematic and Content Analysis of DMT Experiences From a Naturalistic Field Study Frontiers in Psychology December 16, 2021
- Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity. Journal of Affective Disorders February 27, 2024
and 14 more in the library
Cites 41
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
and 36 more in the library